Clinical Trials Browser

Neoplasms × Bevacizumab × Tumor-Agnostic × Clear all

NCT03148418 2026-04-13

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

Phase 3 Active not recruiting

Neoplasms

NCT05862285 2026-04-13

UmbrellaMAX

Phase 3 Recruiting

Neoplasms

NCT01445509 2026-04-06

Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT05112965 2026-04-06

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

Phase 3 Active not recruiting

Neoplasms

NCT03899155 2026-04-01

Pan Tumor Rollover Study

Phase 2 Recruiting

Neoplasms

NCT06031233 2026-03-30

MINUTE

Phase 4 Recruiting

Neoplasms

NCT03203525 2026-02-25

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

Phase 1 Active not recruiting

Neoplasms

NCT04813913 2026-02-06

VASCATAQ

Phase 4 Completed

Neoplasms

NCT03768063 2026-01-29

IMbrella B

Phase 3 Active not recruiting

Neoplasms

NCT06551142 2025-12-18

PanTumor-101

Phase 1 Recruiting

Neoplasms

NCT06107413 2025-12-12

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

Phase 2 Active not recruiting

Neoplasms

NCT06311851 2025-11-25

Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases

Phase 1/2 Recruiting

Neoplasm Metastasis, Neoplasms

NCT06796907 2025-10-14

BEHOLD-2

Phase 1/2 Recruiting

Neoplasms

NCT02420509 2025-06-04

Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis

Neoplasms

NCT06232902 2024-12-18

A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers

Phase 1 Completed

Neoplasms

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

Neoplasms

NCT05904457 2023-06-15

BRISK

Phase 2 Unknown

Neoplasm Metastasis, Neoplasms

NCT01588184 2020-11-05

An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study

Phase 4 Completed

95 enrolled 15 charts

Neoplasms

NCT01633970 2020-10-08

A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

Neoplasms

NCT01514123 2020-09-17

Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT00095459 2019-12-17

BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors

Phase 1 Completed

Neoplasms

NCT01251926 2019-11-15

EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors

Phase 1 Completed

Neoplasms

NCT03659305 2019-02-05

Pharmacokinetic Equivalence and Safety Study of RPH-001 and Avastin®

Phase 1 Completed

Neoplasms

NCT01274624 2018-12-19

Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer

Phase 1 Completed

Neoplasms

NCT02640365 2017-01-31

DOUBLIRI

Phase 1 Completed

Neoplasms

NCT00811993 2016-11-02

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Phase 1 Terminated

Neoplasms

NCT00177307 2016-07-12

Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer

Phase 2 Completed

40 enrolled 8 charts

Neoplasms

NCT00809133 2016-03-14

Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours

Phase 1 Completed

83 enrolled 42 charts

Neoplasms

NCT00222729 2016-02-15

Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer

Phase 2 Completed

42 enrolled 8 charts

Neoplasms

NCT00740168 2016-01-21

BevaRet

Neoplasms

NCT01057264 2015-11-18

HAI Abraxane With Gemcitabine and Bevacizumab

Phase 1 Completed

Neoplasms

NCT00585377 2015-09-24

Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer

Phase 2 Completed

50 enrolled 7 charts

Neoplasms

NCT00448136 2015-01-22

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Phase 2 Completed

83 enrolled 18 charts

Neoplasms

NCT01193595 2014-12-03

Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT02031991 2014-08-15

A Pharmacokinetic Study Comparing PF-06439535 And Bevacizumab In Healthy Male Volunteers (REFLECTIONS B739-01)

Phase 1 Completed

Neoplasms

NCT00109057 2013-06-21

An Extension Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study

Phase 2 Completed

Neoplasms

NCT00226005 2012-05-09

PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma

Phase 2 Completed

Adenocarcinoma, Neoplasm Metastasis, Neoplasms

NCT00395434 2011-10-31

Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasm Metastasis, Neoplasms

NCT01271166 2011-01-06

Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer

Phase 1 Terminated

Neoplasms

NCT00845884 2009-02-18

Phase I/II Study of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Advanced Gastric Cancer

Phase 1/2 Unknown

Neoplasms

NCT00611793 2009-01-23

PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies

Phase 1 Completed

Neoplasms